|
1
|
Cruz-Rodriguez N, Combita AL and Zabaleta
J: Epigenetics in hematological malignancies. Methods Mol Biol.
1856:87–101. 2018. View Article : Google Scholar
|
|
2
|
Upadhyay VA and Fathi AT: Induction
chemotherapy in acute myeloid leukaemia: Origins and emerging
directions. Curr Opin Hematol. 25:67–74. 2018. View Article : Google Scholar
|
|
3
|
Stahl M, Kohrman N, Gore SD, Kim TK,
Zeidan AM and Prebet T: Epigenetics in cancer: A hematological
perspective. PLoS Genet. 12:e10061932016. View Article : Google Scholar
|
|
4
|
Swerdlow SH, Campo E, Pileri SA, Harris
NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz
AD and Jaffe ES: The 2016 revision of the World Health Organization
classification of lymphoid neoplasms. Blood. 127:2375–2390. 2016.
View Article : Google Scholar
|
|
5
|
Klener P and Klanova M: Drug resistance in
non-Hodgkin lymphomas. Int J Mol Sci. 21:20812020. View Article : Google Scholar
|
|
6
|
Feugier P: A review of rituximab, the
first anti-CD20 monoclonal antibody used in the treatment of B
non-Hodgkin's lymphomas. Future Oncol. 11:1327–1342. 2015.
View Article : Google Scholar
|
|
7
|
El-Galaly TC, Cheah CY, Kristensen D,
Hutchison A, Hay K, Callréus T and Villa D: Potentials, challenges
and future of chimeric antigen receptor T-cell therapy in
non-Hodgkin lymphomas. Acta Oncol. 59:766–774. 2020. View Article : Google Scholar
|
|
8
|
Swerdlow SH and Cook JR: As the world
turns, evolving lymphoma classifications-past, present and future.
Hum Pathol. 95:55–77. 2020. View Article : Google Scholar
|
|
9
|
Jones SE: Non-Hodgkin lymphomas. JAMA.
234:633–638. 1975. View Article : Google Scholar
|
|
10
|
Li Y, Wang LX, Pang P, Twitty C, Fox BA,
Aung S, Urba WJ and Hu HM: Cross-presentation of tumor associated
antigens through tumor-derived autophagosomes. Autophagy.
5:576–577. 2009. View Article : Google Scholar
|
|
11
|
Gallo S, Gatti S, Sala V, Albano R,
Costelli P, Casanova E, Comoglio PM and Crepaldi T: Agonist
antibodies activating the Met receptor protect cardiomyoblasts from
cobalt chloride-induced apoptosis and autophagy. Cell Death Dis.
5:e11852014. View Article : Google Scholar
|
|
12
|
Yu SF, Zheng B, Go M, Lau J, Spencer S,
Raab H, Soriano R, Jhunjhunwala S, Cohen R, Caruso M, et al: A
novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC)
that overcomes resistance to auristatin-based ADCs. Clin Cancer
Res. 21:3298–3306. 2015. View Article : Google Scholar
|
|
13
|
Mizushima N: Autophagy: Process and
function. Genes Dev. 21:2861–2873. 2007. View Article : Google Scholar
|
|
14
|
Mizushima N and Komatsu M: Autophagy:
Renovation of cells and tissues. Cell. 147:728–741. 2011.
View Article : Google Scholar
|
|
15
|
Jardon MA, Rothe K, Bortnik S, Vezenkov L,
Jiang X, Young RN, Lum JJ and Gorski SM: Autophagy: From structure
to metabolism to therapeutic regulation. Autophagy. 9:2180–2182.
2013. View Article : Google Scholar
|
|
16
|
Mizushima N and Levine B: Autophagy in
mammalian development and differentiation. Nat Cell Biol.
12:823–830. 2010. View Article : Google Scholar
|
|
17
|
Li X, Zhou Y, Li Y, Yang L, Ma Y, Peng X,
Yang S, Liu J and Li H: Autophagy: A novel mechanism of
chemoresistance in cancers. Biomed Pharmacother. 119:1094152019.
View Article : Google Scholar
|
|
18
|
Piya S, Andreeff M and Borthakur G:
Targeting autophagy to overcome chemoresistance in acute
myleogenous leukemia. Autophagy. 13:214–215. 2017. View Article : Google Scholar
|
|
19
|
Levy JMM, Towers CG and Thorburn A:
Targeting autophagy in cancer. Nat Rev Cancer. 17:528–542. 2017.
View Article : Google Scholar
|
|
20
|
Onorati AV, Dyczynski M, Ojha R and
Amaravadi RK: Targeting autophagy in cancer. Cancer. 124:3307–3318.
2018. View Article : Google Scholar
|
|
21
|
Su LY, Luo R, Liu Q, Su JR, Yang LX, Ding
YQ, Xu L and Yao YG: Atg5- and Atg7-dependent autophagy in
dopaminergic neurons regulates cellular and behavioral responses to
morphine. Autophagy. 13:1496–1511. 2017. View Article : Google Scholar
|
|
22
|
Zheng W, Xie W, Yin D, Luo R, Liu M and
Guo F: ATG5 and ATG7 induced autophagy interplays with UPR via PERK
signaling. Cell Commun Signal. 17:422019. View Article : Google Scholar
|
|
23
|
Romanov J, Walczak M, Ibiricu I, Schüchner
S, Ogris E, Kraft C and Martens S: Mechanism and functions of
membrane binding by the Atg5-Atg12/Atg16 complex during
autophagosome formation. EMBO J. 31:4304–4317. 2012. View Article : Google Scholar
|
|
24
|
Williams RA, Woods KL, Juliano L, Mottram
JC and Coombs GH: Characterization of unusual families of ATG8-like
proteins and ATG12 in the protozoan parasite Leishmania major.
Autophagy. 5:159–172. 2009. View Article : Google Scholar
|
|
25
|
Fletcher K, Ulferts R, Jacquin E, Veith T,
Gammoh N, Arasteh JM, Mayer U, Carding SR, Wileman T, Beale R and
Florey O: The WD40 domain of ATG16L1 is required for its
non-canonical role in lipidation of LC3 at single membranes. EMBO
J. 37:e978402018. View Article : Google Scholar
|
|
26
|
Pruenster M, Vogl T, Roth J and Sperandio
M: S100A8/A9: From basic science to clinical application. Pharmacol
Ther. 167:120–131. 2016. View Article : Google Scholar
|
|
27
|
Wang S, Song R, Wang Z, Jing Z, Wang S and
Ma J: S100A8/A9 in inflammation. Front Immunol. 9:12982018.
View Article : Google Scholar
|
|
28
|
Yang J, Anholts J, Kolbe U, Stegehuis-Kamp
JA, Claas FHJ and Eikmans M: Calcium-binding proteins S100A8 and
S100A9: Investigation of their immune regulatory effect in myeloid
cells. Int J Mol Sci. 19:18332018. View Article : Google Scholar
|
|
29
|
Shabani F, Farasat A, Mahdavi M and Gheibi
N: Calprotectin (S100A8/S100A9): A key protein between inflammation
and cancer. Inflamm Res. 67:801–812. 2018. View Article : Google Scholar
|
|
30
|
Yang M, Zeng P, Kang R, Yu Y, Yang L, Tang
D and Cao L: S100A8 contributes to drug resistance by promoting
autophagy in leukemia cells. PLoS One. 9:e972422014. View Article : Google Scholar
|
|
31
|
Yang L, Yang M, Zhang H, Wang Z, Yu Y, Xie
M, Zhao M, Liu L and Cao L: S100A8-targeting siRNA enhances arsenic
trioxide-induced myeloid leukemia cell death by down-regulating
autophagy. Int J Mol Med. 29:65–72. 2012.
|
|
32
|
Ghavami S, Eshragi M, Ande SR, Chazin WJ,
Klonisch T, Halayko AJ, McNeill KD, Hashemi M, Kerkhoff C and Los
M: S100A8/A9 induces autophagy and apoptosis via ROS-mediated
cross-talk between mitochondria and lysosomes that involves BNIP3.
Cell Res. 20:314–331. 2010. View Article : Google Scholar
|
|
33
|
Chourasia AH and Macleod KF: Tumor
suppressor functions of BNIP3 and mitophagy. Autophagy.
11:1937–1938. 2015. View Article : Google Scholar
|
|
34
|
Dhingra A, Jayas R, Afshar P, Guberman M,
Maddaford G, Gerstein J, Lieberman B, Nepon H, Margulets V, Dhingra
R and Kirshenbaum LA: Ellagic acid antagonizes Bnip3-mediated
mitochondrial injury and necrotic cell death of cardiac myocytes.
Free Radic Biol Med. 112:411–422. 2017. View Article : Google Scholar
|
|
35
|
Zhang L, Li L, Leavesley HW, Zhang X,
Borowitz JL and Isom GE: Cyanide-induced apoptosis of dopaminergic
cells is promoted by BNIP3 and Bax modulation of endoplasmic
reticulum-mitochondrial Ca2+ levels. J Pharmacol Exp Ther.
332:97–105. 2010. View Article : Google Scholar
|
|
36
|
Hanna RA, Quinsay MN, Orogo AM, Giang K,
Rikka S and Gustafsson ÅB: Microtubule-associated protein 1 light
chain 3 (LC3) interacts with Bnip3 protein to selectively remove
endoplasmic reticulum and mitochondria via autophagy. J Biol Chem.
287:19094–19104. 2012. View Article : Google Scholar
|
|
37
|
Ma Z, Chen C, Tang P, Zhang H, Yue J and
Yu Z: BNIP3 induces apoptosis and protective autophagy under
hypoxia in esophageal squamous cell carcinoma cell lines: BNIP3
regulates cell death. Dis Esophagus. 30:1–8. 2017. View Article : Google Scholar
|
|
38
|
Ferreri AJM: Therapy of primary CNS
lymphoma: Role of intensity, radiation, and novel agents.
Hematology Am Soc Hematol Educ Program. 2017:565–577. 2017.
View Article : Google Scholar
|
|
39
|
Witkowska M, Smolewski P and Robak T:
Investigational therapies targeting CD37 for the treatment of
B-cell lymphoid malignancies. Expert Opin Investig Drugs.
27:171–177. 2018. View Article : Google Scholar
|
|
40
|
Reagan PM and Barr PM: Chemotherapy-free
treatment in non-Hodgkin lymphoma: A steep learning curve. Lancet
Haematol. 4:e152–e153. 2017. View Article : Google Scholar
|
|
41
|
Rivera Vargas T and Apetoh L: Danger
signals: Chemotherapy enhancers? Immunol Rev. 280:175–193. 2017.
View Article : Google Scholar
|
|
42
|
Gunjur A: Short vs. long course adjuvant
chemotherapy for colon cancer. Lancet Oncol. 19:e2362018.
View Article : Google Scholar
|
|
43
|
Gayle S, Landrette S, Beeharry N, Conrad
C, Hernandez M, Beckett P, Ferguson SM, Xu T, Rothberg J and
Lichenstein H: B-cell non-Hodgkin lymphoma: Selective vulnerability
to PIKFYVE inhibition. Autophagy. 13:1082–1083. 2017. View Article : Google Scholar
|
|
44
|
Zeng X, Li Y, Fan J, Zhao H, Xian Z, Sun
Y, Wang Z, Wang S, Zhang G and Ju D: Recombinant human arginase
induced caspase-dependent apoptosis and autophagy in non-Hodgkin's
lymphoma cells. Cell Death Dis. 4:e8402013. View Article : Google Scholar
|
|
45
|
Fan J, Zeng X, Li Y, Wang S, Wang Z, Sun
Y, Gao H, Zhang G, Feng M and Ju D: Autophagy plays a critical role
in ChLym-1-induced cytotoxicity of non-hodgkin's lymphoma cells.
PLoS One. 8:e724782013. View Article : Google Scholar
|
|
46
|
Wu K, Sun XQ, Wang CQ, Gao TX, Sun P, Wang
Y, Jiang WQ, Li ZM and Huang JJ: Metronomic combination
chemotherapy using everolimus and etoposide for the treatment of
non-Hodgkin lymphoma. Cancer Med. 8:4688–4698. 2019. View Article : Google Scholar
|
|
47
|
Schaaf MB, Keulers TG, Vooijs MA and
Rouschop KM: LC3/GABARAP family proteins: Autophagy-(un)related
functions. FASEB J. 30:3961–3978. 2016. View Article : Google Scholar
|
|
48
|
Birgisdottir AB, Lamark T and Johansen T:
The LIR motif-crucial for selective autophagy. J Cell Sci.
126:3237–3247. 2013.
|
